AbCellera Biologics Inc. Financing Cash Flow
AbCellera Biologics Inc. (ABCL) reported Financing Cash Flow of $13.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $6.39M.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.19M, a 20.47% increase year-over-year.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.12M, a 0.65% decline year-over-year.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $7.37M, a 134.40% increase year-over-year.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $14.08M, a 10.28% increase from fiscal 2024.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $12.77M, a 23.30% increase from fiscal 2023.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $10.36M.
- AbCellera Biologics Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$1.63M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $13.59M 10-Q · filed 2026-08-05 | $17.70M derived: sum of 3 quarters · filed 2026-08-05 | $25.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.19M 10-Q · filed 2026-05-11 | $11.31M derived: sum of 2 quarters · filed 2026-05-11 | $18.68M derived: sum of 3 quarters · filed 2026-05-11 | $15.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.49M derived: sum of 2 quarters · filed 2026-02-24 | $8.11M derived: sum of 3 quarters · filed 2026-08-05 | $14.08M 10-K · filed 2026-02-24 |
| 2025-09-30 | $7.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.00M derived: sum of 2 quarters · filed 2026-08-05 | $9.97M 10-Q · filed 2025-11-06 | $14.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.60M 10-Q · filed 2026-08-05 | $6.74M derived: sum of 3 quarters · filed 2026-08-05 | $9.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.97M 10-Q · filed 2026-05-11 | $10.11M derived: sum of 2 quarters · filed 2026-05-11 | $13.26M derived: sum of 3 quarters · filed 2026-05-11 | $15.91M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.29M derived: sum of 2 quarters · filed 2026-02-24 | $9.94M derived: sum of 3 quarters · filed 2026-02-24 | $12.77M 10-K · filed 2026-02-24 |
| 2024-09-30 | $3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.80M derived: sum of 2 quarters · filed 2025-11-06 | $8.63M 10-Q · filed 2025-11-06 | $12.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.48M 10-Q · filed 2025-08-07 | $9.25M derived: sum of 3 quarters · filed 2026-02-24 | $15.88M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.83M 10-Q · filed 2025-05-08 | $6.60M derived: sum of 2 quarters · filed 2026-02-24 | $13.23M derived: sum of 3 quarters · filed 2026-02-24 | $13.64M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.39M derived: sum of 2 quarters · filed 2026-02-24 | $10.81M derived: sum of 3 quarters · filed 2026-02-24 | $10.36M 10-K · filed 2026-02-24 |
| 2023-09-30 | $6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $7.05M derived: sum of 2 quarters · filed 2024-11-04 | $6.59M 10-Q · filed 2024-11-04 | $6.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$39.00K 10-Q · filed 2024-08-06 | $310.00K derived: sum of 3 quarters · filed 2025-02-27 | $291.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$458.00K 10-Q · filed 2024-05-07 | -$109.00K derived: sum of 2 quarters · filed 2025-02-27 | -$128.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $330.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | -$1.63M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.15M derived: sum of 2 quarters · filed 2023-11-02 | -$1.98M 10-Q · filed 2023-11-02 | -$143.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.96M 10-Q · filed 2023-08-03 | -$124.00K derived: sum of 3 quarters · filed 2024-02-20 | $774.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$3.13M 10-Q · filed 2023-05-04 | -$1.30M derived: sum of 2 quarters · filed 2024-02-20 | -$399.00K derived: sum of 3 quarters · filed 2024-02-20 | -$5.47M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $2.73M derived: sum of 2 quarters · filed 2024-02-20 | -$2.34M derived: sum of 3 quarters · filed 2024-02-20 | -$3.89M 10-K · filed 2024-02-20 |
| 2021-09-30 | $898.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$4.18M derived: sum of 2 quarters · filed 2022-11-08 | -$5.72M 10-Q · filed 2022-11-08 | $604.22M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$6.62M 10-Q · filed 2022-08-09 | $603.32M derived: sum of 3 quarters · filed 2023-02-21 | $588.95M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$1.54M 10-Q · filed 2022-05-10 | $608.40M derived: sum of 2 quarters · filed 2023-02-21 | $594.03M derived: sum of 3 quarters · filed 2023-02-21 | $594.37M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $609.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $595.57M derived: sum of 2 quarters · filed 2023-02-21 | $595.91M derived: sum of 3 quarters · filed 2023-02-21 | $683.65M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$14.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$14.02M derived: sum of 2 quarters · filed 2021-11-10 | $73.71M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $346.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $88.08M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $87.74M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $195.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |